Compare AMCX & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMCX | EDIT |
|---|---|---|
| Founded | 1980 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 492.0M | 422.3M |
| IPO Year | 2011 | 2016 |
| Metric | AMCX | EDIT |
|---|---|---|
| Price | $9.11 | $1.90 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 8 | 13 |
| Target Price | ★ $9.50 | $6.10 |
| AVG Volume (30 Days) | 687.2K | ★ 2.2M |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 132.55 | 37.50 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,311,801,000.00 | $31,937,000.00 |
| Revenue This Year | $5.04 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $6.47 | $1.66 |
| 52 Week High | $12.93 | $3.94 |
| Indicator | AMCX | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 46.92 | 33.51 |
| Support Level | $7.34 | $1.82 |
| Resistance Level | $10.58 | $3.00 |
| Average True Range (ATR) | 0.49 | 0.24 |
| MACD | 0.23 | -0.07 |
| Stochastic Oscillator | 69.41 | 1.35 |
AMC Global Media owns several linear TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network,reached 55 million pay TV households in the US at the end of 2025. The firm also had nearly 10.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.